Tocilizumab: all 334 studies that test it

Page 2 of 4. Open to participants first (53), then studies with results posted, then the rest; newest registration first within each.

• A Study of the Efficacy and Safety of Tocilizumab in Adults With Rheumatoid Arthritis.CompletedNCT01988012Phase 3Results posted
• A Study on Safety and Efficacy of Tocilizumab (RoActemra/Actemra) Alone or in Combination With Non-Biologic Antirheumatics in Participants With Rheumatoid ArthritisCompletedNCT01987479Phase 3Results posted
• An Open-Label Study of RoActemra/Actemra (Tocilizumab) in Patients With Moderate to Severe Active Rheumatoid ArthritisCompletedNCT01951170Phase 3Results posted
• A Study to Evaluate Efficacy of Tocilizumab Administered as Monotherapy or in Combination With Methotrexate and/or Other Disease Modifying Antirheumatic Drugs (DMARDs) in Rheumatoid Arthritis (RA) ParticipantsCompletedNCT01941940Phase 3Results posted
• A Study of Subcutaneous Tocilizumab as Monotherapy and/or in Combination With Non-Biologic Disease Modifying Anti-Rheumatic Drugs (DMARDs) in Participants With Rheumatoid ArthritisCompletedNCT01941095Phase 3Results posted
• A Study of Subcutaneously (SC) Administered Tocilizumab (TCZ) in Participants With Polyarticular-Course Juvenile Idiopathic Arthritis (pJIA)CompletedNCT01904279Phase 1Results posted
• An Efficacy and Safety Study of Tocilizumab (RoActemra/Actemra) in Participants With Giant Cell Arteritis (GCA)CompletedNCT01791153Phase 3Results posted
• A Long-Term Extension Study of WA22763 and NA25220 of Subcutaneous RoActemra/Actemra (Tocilizumab) in Patients With Moderate to Severe Rheumatoid ArthritisCompletedNCT01772316Phase 3Results posted
• Phase II Study of Tocilizumab for Patients With Glucocorticoid-refractory Acute GVHD After Allogeneic Hematopoetic Stem Cell Transplant (HSCT)TerminatedNCT01757197Phase 2Results posted
• A Long-Term Extension Study of WA22762 to Evaluate Safety and Efficacy of Subcutaneous Tocilizumab in Participants With Moderate to Severe Rheumatoid Arthritis (RA).CompletedNCT01734993Phase 3Results posted
• A Study of Decreased Dose Frequency in Participants With Systemic Juvenile Arthritis Who Experience Laboratory Abnormalities During Treatment With RoActemra/Actemra (Tocilizumab)CompletedNCT01734382Phase 4Results posted
• Musculoskeletal Ultrasound in Predicting Early Dose Titration With TocilizumabCompletedNCT01717859Phase 4Results posted
• A Long-term Safety Extension Study of Tocilizumab in Brazilian Participants With Rheumatoid Arthritis (RA) Who Completed the Studies ML21530 and MA21488CompletedNCT01715831Phase 4Results posted
• An Open-Label Trial of Tocilizumab in SchizophreniaCompletedNCT01696929Phase 1Results posted
• Tocilizumab for the Treatment of Behcet's SyndromeTerminatedNCT01693653Phase 2Results posted
• A Long-Term Extension Study of RoActemra/Actemra (Tocilizumab) in Patients With Juvenile Idiopathic Arthritis From France Who Completed WA19977 Core StudyCompletedNCT01673919Phase 3Results posted
• A Long Term Extension Study of WA19926 (NCT01007435) of Tocilizumab (RoActemra/Actemra) in Participants With Early, Moderate to Severe Rheumatoid Arthritis (RA)CompletedNCT01668966Phase 3Results posted
• A Long-Term Extension Study of RoActemra/Actemra (Tocilizumab) in Patients With Juvenile Idiopathic Arthritis Who Completed WA19977 Core StudyCompletedNCT01667471Phase 3Results posted
• A Long-Term Extension Study to WA19926 (NCT01007435) of Tocilizumab in Participants With Early, Moderate to Severe Rheumatoid ArthritisTerminatedNCT01665430Phase 3Results posted
• An Extension Study of WA19926 of the Long-Term Safety of Tocilizumab (RoActemra/Actemra) in Patients With Early Moderate to Severe Rheumatoid ArthritisCompletedNCT01664598Phase 3Results posted
• A Long-Term Extension Study of WA22762 and NA25220 of Subcutaneous (SC) Tocilizumab (TCZ) in Moderate to Severe Rheumatoid Arthritis (RA)CompletedNCT01662063Phase 3Results posted
• A Long-Term Extension Study of WA19926 on the Safety of Tocilizumab (RoActemra/Actemra) in Participants With Early Moderate to Severe Rheumatoid ArthritisCompletedNCT01655381Phase 3Results posted
• A Long-Term Safety Extension Study of WA19926 in Participants With Rheumatoid ArthritisCompletedNCT01649804Phase 3Results posted
• A Study of RoActemra/Actemra (Tocilizumab) in Patients With Active Rheumatoid Arthritis Who Have an Inadequate Response to DMARDs (REMISSION)CompletedNCT01610791Phase 3Results posted
• Tocilizumab in the Management of Juvenile Idiopathic Arthritis Associated UveitisTerminatedNCT01603355Phase 1/2Results posted
• A Safety Study of Tocilizumab to Improve Transplant Rates in Highly Sensitized Patients Awaiting Kidney TransplantationCompletedNCT01594424Phase 1/2Results posted
• A Study of RoActemra/Actemra (Tocilizumab) With or Without Methotrexate in Patients With Mild to Moderate Rheumatoid Arthritis With an Inadequate Response to MethotrexateCompletedNCT01587989Phase 3Results posted
• An Extension Study to WA19977 in Patients With Active Polyarticular-Course Juvenile Idiopathic ArthritisTerminatedNCT01575769Phase 3Results posted
• A Study of RoActemra/Actemra (Tocilizumab) Versus Placebo in Patients With Systemic SclerosisCompletedNCT01532869Phase 3Results posted
• Tocilizumab for Treatment of Steroid Refractory Acute Graft-versus-Host DiseaseTerminatedNCT01475162Phase 1/2Results posted
• A Study in Patients With Moderate to Severe Active Rheumatoid Arthritis Comparing Different Infusion Durations of RoActemra/Actemra (Tocilizumab) TreatmentCompletedNCT01468077Phase 2Results posted
• Tocilizumab for Patients With Giant Cell ArteritisCompletedNCT01450137Phase 2Results posted
• Tocilizumab for KSHV-Associated Multicentric Castleman DiseaseCompletedNCT01441063Phase 2Results posted
• A Study of RoActemra/Actemra (Tocilizumab) in Combination With Methotrexate Versus RoActemra/Actemra Monotherapy in Patients With Rheumatoid Arthritis and an Inadequate Response to MethotrexateCompletedNCT01399697Phase 4Results posted
• Study of Tocilizumab to Treat Polymyalgia RheumaticaCompletedNCT01396317Phase 2Results posted
• A Study of RoActemra/Actemra (Tocilizumab) in Combination With Methotrexate in Patients With Active Rheumatoid Arthritis Who Have an Inadequate Response to Non-biologic DMARDsCompletedNCT01353859Phase 3Results posted
• A Study of Tocilizumab in Comparison to Etanercept in Participants With Rheumatoid Arthritis and Cardiovascular Disease Risk FactorsCompletedNCT01331837Phase 4Results posted
• A Study of RoActemra/Actemra (Tocilizumab) in Patients With Rheumatoid Arthritis Who Have an Inadequate Response to DMARDs or Anti-TNFCompletedNCT01326962Phase 3Results posted
• A Study of RoActemra/Actemra (Tocilizumab) Versus Adalimumab in Combination With Methotrexate (MTX) in Patients With Moderate to Severe Active Rheumatoid Arthritis And an Inadequate Response to Treatment With Only One Tumor Necrosis Factor (TNF)-InhibitorTerminatedNCT01283971Phase 4Results posted
• An Open-label Study With Tocilizumab in Patients With Rheumatoid Arthritis in a Local EnvironmentCompletedNCT01254331Phase 3Results posted
• A Study of RoActemra/Actemra (Tocilizumab) in Combination With DMARDs Versus Current Best Practice DMARD Therapy in Patients With Rheumatoid ArthritisTerminatedNCT01251120Phase 4Results posted
• A Study of RoActemra/Actemra (Tocilizumab) in Patients With Moderate to Severe Rheumatoid ArthritisCompletedNCT01245439Phase 3Results posted
• A Study of RoActemra/Actemra (Tocilizumab) in Combination With Methotrexate in Patients With Active Rheumatoid Arthritis Who Have an Inadequate Response to Disease-Modifying Antirheumatic Drugs (DMARDs) (ALABASTER)CompletedNCT01235507Phase 3Results posted
• A Study of RoActemra/Actemra (Tocilizumab) Given Subcutaneously in Combination With Traditional DMARDs in Patients With Moderate to Severe Active Rheumatoid ArthritisCompletedNCT01232569Phase 3Results posted
• A Study of Glucocorticoid Use to Evaluate Systematic Methylprednisolone Reduction in Patients With Rheumatoid Arthritis on Background RoActemra/Actemra (Tocilizumab) (ACT-ALONE)CompletedNCT01219933Phase 4Results posted
• A Study of RoActemra/Actemra (Tocilizumab) in Patients With Ankylosing Spondylitis Who Have Failed Treatment With NSAIDsTerminatedNCT01209702Phase 3Results posted
• A Study of Tocilizumab (RoActemra/Actemra) in Patients With Ankylosing Spondylitis Who Have Had an Inadequate Response to Previous Tumor Necrosis Factor (TNF) Antagonist TherapyTerminatedNCT01209689Phase 3Results posted
• A Study of the Effects of RoActemra/Actemra (Tocilizumab) on Neutrophils in Patients With Active Rheumatoid Arthritis Who Have an Inadequate Response to Biologic and/or Non-biologic DMARDs.CompletedNCT01195272Phase 4Results posted
• A Study to Compare Subcutaneous Versus Intravenous Administration of RoActemra/Actemra (Tocilizumab) in Participants With Moderate to Severe Active Rheumatoid ArthritisCompletedNCT01194414Phase 3Results posted
• A Study of the Effects of RoActemra/Actemra on Vaccination in Patients With Rheumatoid Arthritis on Background Methotrexate (VISARA)CompletedNCT01163747Phase 4Results posted
• A Study of RoActemra/Actemra (Tocilizumab) in Patients With Active Rheumatoid Arthritis Who Have an Inadequate Response to Current Non-Biologic and/or Biologic DMARDSCompletedNCT01149057Phase 4Results posted
• A Study of Tocilizumab (RoActemra/Actemra) Versus Adalimumab in Patients With Rheumatoid ArthritisCompletedNCT01119859Phase 4Results posted
• A Study of Tocilizumab as Monotherapy or in Combination With DMARDs in Patients With Moderate to Severe Active Rheumatoid ArthritisCompletedNCT01089023Phase 4Results posted
• A Study With Tocilizumab [RoActemra/Actemra] Monotherapy or in Combination With Methotrexate in Patients With Rheumatoid Arthritis (PICTURE)CompletedNCT01063062Phase 3Results posted
• A Study of Tocilizumab in Combination With an Oral Contraceptive in Patients With Rheumatoid ArthritisCompletedNCT01044498Phase 3Results posted
• Single Patient Study to Treat Relapsing Polychondritis With TocilizumabCompletedNCT01041248Not applicableResults posted
• A Study of Tocilizumab and Methotrexate in Combination or as Monotherapy in Treatment-Naïve Patients With Early Rheumatoid ArthritisCompletedNCT01034137Phase 3Results posted
• A Study of Tocilizumab With or Without Methotrexate in Patients With Rheumatoid Arthritis.CompletedNCT01010503Phase 4Results posted
• A Study of Tocilizumab as Monotherapy and in Combination With Methotrexate Versus Methotrexate in Patients With Early Moderate to Severe Rheumatoid ArthritisCompletedNCT01007435Phase 3Results posted
• A Study of Tocilizumab in Combination With Disease-Modifying Anti-Rheumatic Drugs (DMARDs) in Participants With Moderate to Severe Active Rheumatoid Arthritis With an Inadequate Response to DMARDsCompletedNCT00996606Phase 3Results posted
• A Study of Tocilizumab in Patients With Active Polyarticular Juvenile Idiopathic ArthritisCompletedNCT00988221Phase 3Results posted
• TORPEDO Study: A Study on Rapid Effect of Tocilizumab in Patients With Rheumatoid Arthritis With an Inadequate Response to Disease-Modifying Antirheumatic Drugs (DMARDs) or Anti-TNFCompletedNCT00977106Phase 3Results posted
• A Study of Tocilizumab + DMARDs in Patients With Moderate to Severe Active Rheumatoid ArthritisCompletedNCT00951275Phase 3Results posted
• A Study Comparing Infusion Rates of Tocilizumab in Patients With Moderate to Severe Rheumatoid ArthritisCompletedNCT00887341Phase 2Results posted
• An Extension to Study MA21573, Evaluating Tocilizumab in Patients With Active Rheumatoid Arthritis and an Inadequate Response to Current Non-Biological DMARDs and/or Anti-tumor Necrosis Factor (TNF) TherapyCompletedNCT00883753Phase 3Results posted
• Single Patient Use of Tocilizumab in Systemic Onset Juvenile Idiopathic ArthritisTerminatedNCT00868751Not applicableResults posted
• A Study to Assess the Effect of Tocilizumab on Signs and Symptoms in Patients With Rheumatoid ArthritisCompletedNCT00848120Phase 3Results posted
• A Study of Tocilizumab in Patients With Rheumatoid Arthritis Who Have an Inadequate Response to Current Non-Biologic DMARDsCompletedNCT00810277Phase 3Results posted
• A Study of Tocilizumab in Combination With DMARD Therapy in Patients With Active Rheumatoid Arthritis.CompletedNCT00773461Phase 3Results posted
• A Study to Assess Efficacy With Respect to Clinical Improvement in Disease Activity and Safety of Tocilizumab in Patients Wtih Active Rheumatoid Arthritis.CompletedNCT00754559Phase 3Results posted
• An Exploratory Study of Tocilizumab in Patients With Active Rheumatoid Arthritis (RA) and an Inadequate Response to Current Non-Biologic DMARDs and/or Anti-TNF Therapy.CompletedNCT00750880Phase 3Results posted
• A Long-term Extension Study of Tocilizumab (Myeloma Receptor Antibody [MRA]) in Patients With Rheumatoid ArthritisCompletedNCT00721123Phase 3Results posted
• An Extension Study of Tocilizumab (Myeloma Receptor Antibody [MRA]) in Patients Completing Treatment in Tocilizumab Core StudiesCompletedNCT00720798Phase 3Results posted
• A Study of RoActemra/Actemra (Tocilizumab) in Patients With Active Systemic Juvenile Idiopathic Arthritis (JIA)CompletedNCT00642460Phase 3Results posted
• A Study of the Effect of Tocilizumab on Markers of Atherogenic Risk in Patients With Moderate to Severe Rheumatoid ArthritisCompletedNCT00535782Phase 3Results posted
• A Study of Tocilizumab in Combination With DMARDs in Patients With Moderate to Severe Rheumatoid ArthritisCompletedNCT00531817Phase 3Results posted
• Efficacy and Safety of Interleukin-6 Receptor Inhibitor Combined With Endovascular Treatment in Patients With Acute Anterior Circulation Large Vessel Occlusion Stroke -2Active, not recruitingNCT07263776Phase 3
• Interplay Between Interleukin-6 and Glucagon in the Regulation of Human Amino Acid and Protein HomeostasisCompletedNCT06721910Not applicable
• Safety and Efficacy of Tocilizumab in Patients With Myelin Oligodendrocyte Glycoprotein Antibody-associated DiseaseActive, not recruitingNCT06452537Phase 2/3
• Tocilizumab for Painful Chronic PancreatitisActive, not recruitingNCT06426160Phase 2
• Effect of Interleukin-6 Receptor Inhibition in Patients With Ischemic Stroke Undergoing Endovascular TreatmentCompletedNCT06238024Phase 2/3
• Efficacy and Safety of Tocilizumab for TAOWithdrawnNCT06087731Phase 2
• Rituxmab Versus IL-6 in Treating ILDCompletedNCT05963048Phase 2/3
• Phase II Trial of VDJ001 in Patients With Moderate-to-severe Active Rheumatoid ArthritisCompletedNCT05957107Phase 2
• A Study to Evaluate Usability of Subcutaneous Auto-injector of CT-P47 in Patients With Active Rheumatoid ArthritisStatus unknownNCT05725434Phase 3
• Venetoclax and Tocilizumab for the Treatment of Patients With Relapsed or Refractory t(11;14) Multiple MyelomaActive, not recruitingNCT05391750Phase 1
• Low-Dose Dobutamine and Single-Dose Tocilizumab in Acute Myocardial Infarction With High Risk of Cardiogenic ShockActive, not recruitingNCT05350592Phase 2
• IL-6 Regulation of Energy Stores During Recovery From an Acute Exercise BoutCompletedNCT05349149Not applicable
• Possible Immuno-Modulatory Effect of Tocilizumab in Patients With Refractory Status Epilepticus.Status unknownNCT05346666Phase 3
• Combination of Inhaled DNase, Baricitinib and Tocilizumab in Severe COVID-19Status unknownNCT05279391Not applicable
• The Efficacy and Safety of Tocilizumab for Severe RP-ILD Secondary to Systemic DiseasesStatus unknownNCT05181397Phase 2
• A Study Evaluating Tocilizumab in Pediatric Patients Hospitalized With COVID-19CompletedNCT05164133Phase 1
• High-Dose Corticosteroid or Tocilizumab for Clinical Worsening of COVID-19WithdrawnNCT05133635Phase 4
• Tocilizumab Versus Baricitinib in Patients With Severe COVID-19CompletedNCT05082714Not applicable
• Tocilizumab, Ipilimumab, and Nivolumab for the Treatment of Advanced Melanoma, Non-Small Cell Lung Cancer, or Urothelial CarcinomaActive, not recruitingNCT04940299Phase 2
• Efficacy of Tocilizumab in Association to Steroids in Giant Cell Arteritis With Cerebro-vascular InvolvementActive, not recruitingNCT04888221Phase 3
• Comparative Study of 3 Tocilizumab Products in Normal Healthy VolunteeersCompletedNCT04885829Phase 1
• Tocilizumab in Active Moderate-severe Graves' OrbitopathyCompletedNCT04876534Phase 2
• Interleukin-6 Inhibitors and Drug-drug Interactions in Patients With Rheumatoid ArthritisTerminatedNCT04842981Phase 1/2
• Evaluation of the Safety of Use of Anti-IL6 Receptor Antibodies to Reduce Allo-sensitization Post Allograft NephrectomyCompletedNCT04779957Phase 2

← Tocilizumab overview